Drug Trial Radar · NCT05019521
A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Last checked: Nov 20, 2026Latest source record: Sep 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
365
Actual
Start
Aug 23, 2021
Primary completion
Jul 5, 2024
Study completion Jan 21, 2025
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Aug 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a dose finding study designed to evaluate the efficacy, safety, and pharmacokinetics of danicopan in participants with GA secondary to AMD. The study consists of a Screening Period of up to 6 weeks, a 104-week masked Treatment Period, followed by a 30-day Follow-up after the last dose. This study will have 4 treatments arms: 100 milligrams (mg) twice daily (bid), 200 mg bid, 400 mg once daily (qd), and matching placebo.
Conditions
- Geographic Atrophy
Interventions
DanicopanDrug
Oral tablet.
PlaceboDrug
Oral tablet.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Change From Baseline to Week 52 in the Square Root (Sqrt) of Total Geographic Atrophy (GA) Lesion Area in the Study Eye as Measured by Fundus Autofluorescence (FAF)Time frame: Baseline, Week 52
Locations
128 sites in 13 countries. Site status is shown where the registry gives one.
Research Site
Phoenix, Arizona
Research Site
Beverly Hills, California
Research Site
Encino, California
Research Site
Fresno, California
Research Site
Fullerton, California
Research Site
La Jolla, California
Research Site
Pasadena, California
Research Site
Sacramento, California
Research Site
San Mateo, California
Research Site
Walnut Creek, California
Research Site
Colorado Springs, Colorado
Research Site
Longmont, Colorado
Research Site
Waterford, Connecticut
Research Site
Clearwater, Florida
Research Site
Coral Springs, Florida
Research Site
Deerfield Beach, Florida
Research Site
Naples, Florida
Research Site
Palm Beach Gardens, Florida
Research Site
St. Petersburg, Florida
Research Site
Augusta, Georgia
Research Site
New Albany, Indiana
Research Site
West Des Moines, Iowa
Research Site
Hagerstown, Maryland
Research Site
Rosedale, Maryland
Research Site
Towson, Maryland
Research Site
Springfield, Massachusetts
Research Site
Southaven, Mississippi
Research Site
Reno, Nevada
Research Site
Teaneck, New Jersey
Research Site
Great Neck, New York
Research Site
Durham, North Carolina
Research Site
Cincinnati, Ohio
Research Site
Portland, Oregon
Research Site
Springfield, Oregon
Research Site
Kingston, Pennsylvania
Research Site
Monroeville, Pennsylvania
Research Site
Philadelphia, Pennsylvania
Research Site
Philadelphia, Pennsylvania
Research Site
Greenville, South Carolina
Research Site
Ladson, South Carolina
Showing 40 of 128 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.